GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Trulicity vs Ozempic in India — Dulaglutide or Semaglutide?

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly GLP-1 injections approved in India for type 2 diabetes. In SUSTAIN-7, the only head-to-head trial, semaglutide lowered HbA1c and body weight more at each dose pairing tested. In India Ozempic is also cheaper — ₹5,660–9,100 a month versus about ₹11,300 for Trulicity — and generic semaglutide costs less again.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Trulicity vs Ozempic — at a glance

AttributeTrulicityOzempic
Active ingredientDulaglutideSemaglutide
Drug classGLP-1 receptor agonistGLP-1 receptor agonist
Marketed in India byCipla (made by Eli Lilly)Novo Nordisk (Extensior: Abbott)
Indication (India)Type 2 diabetesType 2 diabetes
Strengths sold in India0.75 mg, 1.5 mg0.25 mg, 0.5 mg, 1 mg
FrequencyOnce weeklyOnce weekly
PenSingle-dose pen — a new pen each weekMulti-dose FlexTouch pen — about one pen a month
HbA1c change (SUSTAIN-7, 40 weeks)−1.1% (0.75 mg) · −1.4% (1.5 mg)−1.5% (0.5 mg) · −1.8% (1 mg)
Weight change (SUSTAIN-7, top doses)−3.0 kg (1.5 mg)−6.5 kg (1 mg)
Approved for weight loss in IndiaNoNo — obesity-dose semaglutide is sold as Wegovy
Approx. monthly price (India, Sep 2026)≈ ₹11,300 (₹5,669 per 2-pen pack)₹5,660 – ₹9,100
Generic available in IndiaNone foundYes — generic semaglutide from ₹220/shot
Prescription requiredYesYes (Schedule H)

Efficacy — what the trials show

Trulicity

Dulaglutide’s evidence base is the AWARD trial programme, plus cardiovascular-outcomes data from the REWIND trial. In SUSTAIN-7 — the one head-to-head against semaglutide, run for 40 weeks in 1,201 adults with type 2 diabetes already on metformin — dulaglutide lowered HbA1c by 1.1% at 0.75 mg and 1.4% at 1.5 mg, with about 3 kg of weight loss at 1.5 mg.

Ozempic

In the same SUSTAIN-7 trial, semaglutide lowered HbA1c by 1.5% at 0.5 mg and 1.8% at 1 mg, and body weight by 6.5 kg at 1 mg — more than dulaglutide at each dose pairing. Semaglutide also has its own cardiovascular-outcomes data (SUSTAIN-6). Individual results vary; your doctor weighs these numbers against your history.

Cost in India (2026)

Trulicity

Trulicity sells at an MRP of about ₹5,669 for a pack of two single-dose pens, the same price for 0.75 mg and 1.5 mg. At one pen a week that is roughly ₹11,300 a month. It is made by Eli Lilly and distributed in India by Cipla (since a 2021 agreement). We found no generic dulaglutide marketed in India.

Ozempic

Ozempic costs ₹5,660–9,100 a month after Novo Nordisk’s 2026 price cuts, depending on dose. Since India’s semaglutide patent expired in March 2026, DCGI-approved generic semaglutide is also available from about ₹220 per weekly shot — well below either branded option.

Side effects

Trulicity

Typical GLP-1 side effects: nausea, diarrhoea, vomiting and abdominal discomfort, most common when starting or stepping up the dose. Rarer class-wide risks include pancreatitis, gallbladder problems and a thyroid C-cell tumour warning based on animal data — people with a personal or family history of medullary thyroid cancer should not use it.

Ozempic

The same class profile as dulaglutide — nausea, diarrhoea, vomiting and constipation, mostly while the dose is being increased, which is why semaglutide is started low and stepped up every four weeks. The rare class-wide risks (pancreatitis, gallbladder events, the thyroid C-cell warning) apply equally.

Which one should you consider?

Pick Trulicity if

  • You are already stable and well controlled on it
  • You prefer a ready-to-use single-dose pen each week, with no dose dialling
  • Your doctor prefers it for your particular history

Pick Ozempic if

  • You want the larger HbA1c and weight reduction seen in SUSTAIN-7
  • Cost matters — Ozempic is cheaper, and generic semaglutide is cheaper still
  • You may later need an obesity-dose option (semaglutide 2.4 mg, sold as Wegovy)

Frequently asked questions

Is Ozempic better than Trulicity?+
In the only head-to-head trial, SUSTAIN-7, semaglutide (Ozempic) lowered HbA1c and body weight more than dulaglutide (Trulicity) at each dose pairing tested — for example −1.8% vs −1.4% HbA1c and −6.5 kg vs −3.0 kg at the top doses. “Better” for you also depends on your other conditions, how you tolerate each drug and cost, so the choice belongs with your doctor.
How much does Trulicity cost in India?+
Trulicity’s MRP is about ₹5,669 for a pack of two single-dose pens, the same for 0.75 mg and 1.5 mg (1mg, Apollo and PharmEasy, September 2026). Used weekly, that is roughly ₹11,300 a month. It is made by Eli Lilly and distributed in India by Cipla. Prices change — confirm with your pharmacist.
Can I switch from Trulicity to Ozempic?+
Yes, but only under your doctor’s supervision. Both are weekly injections, so a switch is usually timed to your next scheduled dose, and your doctor will choose the starting semaglutide dose rather than jumping to the top dose. Don’t take both, and don’t switch on your own.
Is Trulicity approved for weight loss in India?+
No. In India Trulicity is a type 2 diabetes medicine. Some people lose a little weight on it, but it is not indicated for weight management. The GLP-1 options sold in India for weight management are obesity-dose semaglutide (Wegovy and some generics) and tirzepatide (Mounjaro, Yurpeak).
Are Trulicity 3 mg and 4.5 mg available in India?+
Not that we could find. Indian pharmacies list only the 0.75 mg and 1.5 mg pens. The higher 3 mg and 4.5 mg doses were approved in the US in 2020, but we found no Indian listing for them as of September 2026.
Is there a generic version of Trulicity in India?+
We found no generic dulaglutide marketed in India as of September 2026. Generic semaglutide, by contrast, has been widely available since the Indian patent expired in March 2026 — see our branded vs generic semaglutide comparison.

Related comparisons

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.